Mode
Text Size
Log in / Sign up

Observational genomic study of over 500 Indian breast tumors identifies novel mutations and subtypesStudy maps genetic landscape of breast cancer tumors from over 500 patients in India

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider genomic insights from Indian breast tumors as descriptive biology, not proven clinical guidance.

This observational study performed whole-genome and transcriptome analysis on over 500 clinically annotated, treatment-naive breast tumors from India. No specific intervention, comparator, or primary outcome was reported. The research aimed to characterize the genomic landscape of this population.

The analysis identified novel significantly mutated genes under positive selection and uncovered recurrent copy number alterations driving lipid metabolic reprogramming. Mutational processes were dominated by DNA repair deficiency, APOBEC activity, and genome instability. The study revealed three genomic features significantly associated with poor post-surgical recurrence-free survival and distinct intrinsic subtypes with divergent immune landscapes. A novel transcriptomic signature capturing a HER2-like transcriptional state within triple-negative breast cancer patients was also found. The research revealed clinically actionable germline and somatic alterations with high significance.

Safety and tolerability data were not reported. Key limitations, including specific methodological constraints or potential biases, were not detailed in the provided information. The study's practice relevance is framed as providing critical insights into tumor biology and advancing precision oncology, but its observational nature precludes causal claims about treatment effects. The findings are descriptive and require validation in prospective clinical settings.

Scientists conducted a detailed genetic analysis of breast cancer tumors from over 500 patients in India who had not yet received treatment. They looked at the entire genome and gene activity to create a map of the cancer's biology. This type of research is called an observational study, which means it describes what is present but cannot prove what causes it.

The study found several new genetic features in these tumors. These include specific gene mutations that may help the cancer evade the immune system, changes related to how cancer cells use fat for energy, and three genetic patterns linked to a higher chance of the cancer returning after surgery. The researchers also identified genetic changes that could potentially be targeted by existing or future drugs.

It is important to be cautious with these results. This was not a clinical trial, so the findings do not show that any specific treatment will work. The study provides a valuable, detailed picture of breast cancer genetics in this population, which is a crucial first step for future research aimed at developing more personalized care.

What this means for you:
Early genetic study describes features of breast cancer; more research is needed to develop new treatments.

Study Details

EvidenceLevel 5
PublishedMar 2026
View Original Abstract ↓
Breast cancer remains the leading cause of cancer-related mortality among women globally, yet South Asian populations are critically underrepresented in genomic studies. Here, we present whole-genome and transcriptome analyses of over 500 treatment-naive, clinically annotated breast tumors from India, representing the first large-scale integrative omics characterization of this population. In addition to established drivers, we identify novel significantly mutated genes, including ISM2, TERF2, and DHRSX, under positive selection, along with previously unreported potentially pathogenic somatic variants. Notably, the distribution of key hotspot mutations appears shaped by immune escape pressures. We uncover recurrent copy number alterations driving lipid metabolic reprogramming (e.g., NCEH1 and PLD1 amplifications) and complex structural events, including IKZF3 promoter hijacking leading to ERBB2 overexpression and TTC28-associated genomic instability--findings not previously described in breast cancer. Mutational processes are dominated by DNA repair deficiency, APOBEC activity, and genome instability. We identify three genomic features significantly associated with poor post-surgical recurrence-free survival. Transcriptomic profiling reveals distinct intrinsic subtypes with divergent immune landscapes, including a high-risk HER2-androgenic cluster with the worst outcomes. Additionally, we find a novel transcriptomic signature that robustly captures a HER2-like transcriptional state within triple-negative breast cancer patients - with major implications for TNBC treatment. Finally, clinically actionable germline and somatic alterations are revealed with high significance, highlighting opportunities for therapeutic repurposing. Together, the study establishes a comprehensive molecular atlas of breast cancer in an underrepresented population, providing critical insights into tumour biology and advancing precision oncology.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.